A phase I/II non-randomized, open-label, dose-finding study of ispinesib (SB-715992) followed by a fixed-dose study in chemotherapy-naive patients with metastatic breast cancer (MBC).

Trial Profile

A phase I/II non-randomized, open-label, dose-finding study of ispinesib (SB-715992) followed by a fixed-dose study in chemotherapy-naive patients with metastatic breast cancer (MBC).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Jan 2010

At a glance

  • Drugs Ispinesib (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Cytokinetics
  • Most Recent Events

    • 20 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Jun 2009 Interim data from the ongoing phase I portion were presented at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO), according to a Cytokinetics media release.
    • 29 Aug 2008 Interim results will be presented at the September 2008 ASCO Breast Cancer Symposuim.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top